NCT02144038View on ClinicalTrials.gov

Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 23, 2014

Primary Completion Date

October 28, 2015

Study Completion Date

October 28, 2015

Conditions
Relapsed and Refractory Multiple Myeloma
Interventions
DRUG

LGH447

pan-PIM inhibitor

DRUG

BYL719

PI3K-alpha inhibitor

Trial Locations (8)

3181

Novartis Investigative Site, Prahran

20133

Novartis Investigative Site, Milan

24105

Novartis Investigative Site, Kiel

69120

Novartis Investigative Site, Heidelberg

98105

Seattle Cancer Care Alliance Oncology Dept, Seattle

169608

Novartis Investigative Site, Singapore

77030-4009

University of Texas/MD Anderson Cancer Center Dept.ofMDAndersonCancerCtr(SC), Houston

53792-6164

University of Wisconsin / Paul P. Carbone Comp Cancer Center Dept of Onc., Madison

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY